Zacks: Analysts Expect China Biologic Products Holdings, Inc. (CBPO) Will Post Earnings of $1.11 Per Share

Wall Street brokerages forecast that China Biologic Products Holdings, Inc. (NASDAQ:CBPO) will report earnings of $1.11 per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for China Biologic Products’ earnings. China Biologic Products reported earnings per share of $0.95 during the same quarter last year, which would suggest a positive year-over-year growth rate of 16.8%. The company is expected to issue its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that China Biologic Products will report full-year earnings of $5.22 per share for the current fiscal year, with EPS estimates ranging from $5.17 to $5.26. For the next year, analysts anticipate that the firm will report earnings of $5.75 per share, with EPS estimates ranging from $5.49 to $6.00. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow China Biologic Products.

Separately, Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. China Biologic Products currently has a consensus rating of “Hold” and an average target price of $137.50.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jennison Associates LLC lifted its stake in China Biologic Products by 0.8% in the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after acquiring an additional 44 shares during the last quarter. OxFORD Asset Management LLP raised its position in shares of China Biologic Products by 1.6% in the second quarter. OxFORD Asset Management LLP now owns 14,748 shares of the biopharmaceutical company’s stock valued at $1,668,000 after purchasing an additional 236 shares during the period. Legal & General Group Plc raised its position in shares of China Biologic Products by 41.2% in the third quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock valued at $274,000 after purchasing an additional 865 shares during the period. California Public Employees Retirement System raised its position in shares of China Biologic Products by 3.1% in the second quarter. California Public Employees Retirement System now owns 29,500 shares of the biopharmaceutical company’s stock valued at $3,336,000 after purchasing an additional 900 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of China Biologic Products by 15.4% in the first quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock valued at $1,432,000 after purchasing an additional 1,906 shares during the period. Hedge funds and other institutional investors own 65.67% of the company’s stock.

China Biologic Products (NASDAQ:CBPO) traded down $2.09 during mid-day trading on Wednesday, hitting $76.08. 170,200 shares of the company traded hands, compared to its average volume of 239,632. The firm has a market capitalization of $2,158.22, a PE ratio of 17.41, a P/E/G ratio of 1.28 and a beta of 1.78. China Biologic Products has a twelve month low of $72.21 and a twelve month high of $120.46.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect China Biologic Products Holdings, Inc. (CBPO) Will Post Earnings of $1.11 Per Share” was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/13/zacks-analysts-expect-china-biologic-products-holdings-inc-cbpo-will-post-earnings-of-1-11-per-share.html.

China Biologic Products Company Profile

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply